)
Visual22 Oct 2025
Epiroc's cash spent on M&A
Ovid Therapeutics (OVID) investor relations material
Ovid Therapeutics Study Result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Result summary3 Oct, 2025
Pipeline overview and unmet need
OV329 is a next-generation GABA aminotransferase inhibitor targeting neural hyperexcitability disorders, including drug-resistant epilepsy and CNS diseases, with a differentiated mechanism from existing therapies.
Pipeline includes OV329 for treatment-resistant epilepsies and KCC2 direct activators for CNS indications.
Significant unmet need remains in epilepsy, with many patients experiencing uncontrolled seizures despite multiple approved drugs.
OV329 aims to address safety and tolerability issues seen with first-generation GABA modulators like vigabatrin.
Market opportunity exceeds $1 billion annually, with a target population of 65,000 adults in the U.S.
Study design and objectives
Phase 1 trial evaluated OV329 in 68–69 healthy volunteers, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics across single and multiple ascending dose cohorts (1–5 mg).
Extensive biomarker analyses included TMS, MRS, and EEG to measure GABAergic inhibition and brain engagement.
OV329 was compared to placebo and to published data for vigabatrin, a first-generation GABA-AT inhibitor.
The Phase 1 study evaluated safety, pharmacokinetics, pharmacodynamics, and biomarker effects in healthy volunteers to inform Phase 2 dosing.
OV329 is designed for once-daily oral dosing, with lower anticipated human doses compared to existing therapies.
Safety and tolerability results
OV329 demonstrated a strong safety profile with only mild, transient adverse events and no serious treatment-related or ophthalmic events.
No ocular or retinal changes were observed, supported by rigorous ophthalmic safety monitoring and preclinical studies.
No evidence of drug accumulation in the eye, differentiating OV329 from vigabatrin and reducing risk of vision loss.
No titration is anticipated for future dosing due to the clean safety profile.
All potentially treatment-related adverse events were mild and transient, including headache, drowsiness, and metallic taste.
OV329 ocular safety: market differentiation
OV4071 ketamine challenge: derisking schizophrenia?
OV329 Phase IIa: expected seizure reduction?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ovid Therapeutics earnings date
Q3 202511 Nov, 2025
Next Ovid Therapeutics earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for rare neurological disorders. The company specializes in small-molecule and genetic-based therapies targeting conditions such as epilepsies and neurodevelopmental syndromes. Its research and development efforts aim to advance novel drug candidates through clinical trials and regulatory approvals. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage